Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
118
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

109
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
109
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

3.5K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of care-pathways of older adults hospitalized for influenza-like illness before institutionalization: a French SNDS-based study.

BMC health services research·2026
Same author

Development of a self-questionnaire (APP-Chutes®) for pre-screening older persons at moderate or high risk of falling according to the World Falls Guidelines.

Geriatrie et psychologie neuropsychiatrie du vieillissement·2026
Same author

[Edgar Morin and Complexity: The Inspiration Behind the Specifications Framework for the Gerontopoles of the French Union of Gerontopoles].

Geriatrie et psychologie neuropsychiatrie du vieillissement·2026
Same author

Allergic rhinitis in the elderly. In collaboration with ARIA guidelines.

The journal of allergy and clinical immunology. In practice·2026
Same author

Safety of Fluoroquinolones and Cotrimoxazole in Urinary Tract Infections in Older Males.

Open forum infectious diseases·2026
Same author

Assessment of the "world guidelines for falls prevention and management" algorithm in older volunteers.

Aging clinical and experimental research·2026

Related Experiment Video

Updated: Jun 11, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

[Clostridioides difficile infections: Update and therapeutic guidelines].

Gilles Berrut1, Claire Roubaud Baudron2, Marc Paccalin3

  • 1Nantes University, Nantes University Hospital, University Hospital Center for Clinical Gerontology, Nantes, France, Gérontopôle des Pays-de-la-Loire, France.

Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement
|October 8, 2024
PubMed
Summary
This summary is machine-generated.

Clostridioides difficile infection (CDI) is a growing health threat. Effective CDI management requires prevention, careful antibiotic use, and updated treatments, with ongoing research improving patient outcomes.

Keywords:
Clostridioides difficileelderly patiententerocolitistreatment review

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.7K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K

Related Experiment Videos

Last Updated: Jun 11, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.7K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Gastroenterology

Context:

  • Clostridioides difficile infection (CDI) presents increasing incidence, severity, and treatment challenges.
  • Complications include pseudomembranous colitis (PMC) and toxic megacolon.
  • Accurate diagnosis integrates clinical, microbiological, and imaging findings.

Purpose:

  • To outline current strategies for managing Clostridioides difficile infection (CDI).
  • To highlight diagnostic criteria and therapeutic options for CDI.
  • To emphasize the importance of a multifactorial approach in CDI control.

Summary:

  • CDI management necessitates preventive strategies, judicious antibiotic stewardship, and tailored therapies.
  • Diagnostic methods include toxin assays, PCR, stool cultures, and imaging.
  • Treatment options encompass fidaxomicin, vancomycin, fecal microbiota transplantation (FMT), and bezlotoxumab for recurrence prevention.

Impact:

  • Improved understanding and application of diagnostic and therapeutic guidelines for CDI.
  • Enhanced clinical practices through vigilance and informed decision-making by healthcare professionals.
  • Potential for better patient outcomes and reduced CDI burden through ongoing research and innovation.